Table 2.
Body composition by dual energy X-ray absorptiometry (DEXA) scan
| Variable | ≥30 % Body Fat | <30 % Body Fat | P-Value | ≤60 % Lean Muscle Mass | >60 % Lean Muscle Mass | P-value |
|---|---|---|---|---|---|---|
| N = 8 | N = 2 | N = 4 | N = 6 | |||
| Mean Age, years ± Standard deviation (SD) | 16.3 ± 2.7 | 12.5 ± 3.5 | 0.4 | 15.7 ± 4 | 15.3 ± 2.7 | 0.8 |
| African American, n | 6 | 2 | 0.4 | 4 | 4 | 0.2 |
| Years of SLE ± SD | 4.1 ± 2.5 | 4.5 ± 0.7 | 0.7 | 3.3 ± 1.6 | 5.5 ± 2.6 | 0.2 |
| Physically Active in the past year | ||||||
| Yes | 6 | 2 | 0.9 | 2 | 6 | 0.1 |
| No | 2 | 0 | 2 | 0 | ||
| Malar rash | ||||||
| Present | 6 | 0 | 0.1 | 4 | 2 | 0.07 |
| Absent | 2 | 2 | 0 | 4 | ||
| Kidney Disease | ||||||
| Present | 4 | 1 | 0.9 | 4 | 1 | 0.04 |
| Absent | 4 | 1 | 0 | 5 | ||
| dsDNA Antibody | ||||||
| Present | 8 | 1 | 0.2 | 4 | 5 | 0.9 |
| Absent | 0 | 1 | 0 | 1 | ||
| Ro/La Antibodies | ||||||
| Present | 2 | 0 | 0.9 | 1 | 1 | 0.9 |
| Absent | 6 | 2 | 3 | 5 | ||
| Smith Antibody | ||||||
| Present | 3 | 0 | 0.9 | 3 | 0 | 0.03 |
| Absent | 5 | 2 | 1 | 6 | ||
| Low C3/C4 | ||||||
| Present | 2 | 0 | 0.9 | 2 | 0 | 0.1 |
| Absent | 6 | 2 | 2 | 6 | ||
| Mean SLEDAI, ± SD | 1.3 ± 1.1 | 0 | 0.06 | 2 ± 1.4 | 0.4 ± 0.2 | 0.07 |
| Prednisone | ||||||
| Taking | 4 | 0 | 0.4 | 3 | 1 | 0.1 |
| Not taking | 4 | 2 | 1 | 5 | ||
| Cumulative prednisone dose, mg (range) | 900 (0–3600) | 0 | 0.1 | 1725 (0–3600) | 50 (0–300) | 0.1 |
| Hydroxychloroquine | ||||||
| Taking | 8 | 2 | -- | 4 | 6 | -- |
| Not taking | ||||||
| Methotrexate | ||||||
| Taking | 2 | 0 | 0.9 | 1 | 1 | 0.9 |
| Not taking | 6 | 2 | 3 | 5 | ||
| Mycophenolate mofetil | ||||||
| Taking | 3 | 1 | 0.9 | 2 | 2 | 0.9 |
| Not taking | 5 | 1 | 2 | 4 | ||